東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Developing Base Editing and Prime Ed...

Brooks, Dominique,

FindBook

Google Book

Amazon

博客來

Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria // Dominique Brooks.
作者:	Brooks, Dominique,
面頁冊數:	1 electronic resource (114 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-12, Section: A.
Contained By:	Dissertations Abstracts International86-12A.
標題:	Genetics. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31994101
ISBN:	9798280758025

Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria /
Brooks, Dominique,

Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria /Dominique Brooks. - 1 electronic resource (114 pages)

Source: Dissertations Abstracts International, Volume: 86-12, Section: A.

Phenylketonuria (PKU), the most common inborn error of metabolism, is an autosomal recessive disorder caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. PAH converts phenylalanine (Phe) to tyrosine (Tyr), and impaired activity of PAH leads to the accumulation of blood Phe to neurotoxic levels. Despite existing dietary and medical treatments, chronic Phe elevations persist in most patients, causing neurological and cognitive deficits, particularly those with the most frequent pathogenic variants, such as c.1222C>T (p.R408W) and c.842C>T (p.P281L). Genome editing has the unique ability to directly correct these pathogenic variants and offers the potential for durable and curative therapies to address the unmet medical needs of PKU patients. Through this work, we have established a pipeline to rapidly screen and optimize prime editing or base editing strategies in vitro and deploy them in vivo with either lipid nanoparticles (LNPs) or adeno-associated viral (AAV) vectors on a timescale of months. We created prime-edited variant-bearing hepatocyte cell lines with the aforementioned PAH variants, and in parallel, humanized PKU mouse models. In homozygous or compound heterozygous PKU mice, we observe complete and long-term durable normalization of blood Phe levels (>90% reduction) as soon as 48 hours after treatment, with whole-liver corrective PAH editing as high as >50% with either prime editing or base editing. We have developed therapeutic leads for R408W and P281L to permanently normalize blood Phe levels and definitively treat PKU in these patients-on track for early-phase clinical trials within a few years. Together, these findings support the development of gene-editing therapies as definitive treatments for PKU and establish a framework for the nomination and validation of base and prime editing therapies for PKU and other hepatic inborn errors of metabolism.

English

ISBN: 9798280758025Subjects--Topical Terms:

530508
Genetics.
Subjects--Index Terms:

Gene editing

Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria /
LDR:03388nmm a22004333i 4500 001 2434868
005 20251001062544.5
006 m o d
007 cr|nu||||||||
008 261011s2025 miu||||||m |||||||eng d
020 $a 9798280758025
035 $a (MiAaPQD)AAI31994101
035 $a AAI31994101
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Brooks, Dominique, $e author. $3 3824998
245 1 0 $a Developing Base Editing and Prime Editing Therapies for the Treatment of Phenylketonuria / $c Dominique Brooks.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2025
300 $a 1 electronic resource (114 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-12, Section: A.
500 $a Advisors: Musunuru, Kiran Committee members: Ahrens-Nicklas, Rebecca; Jain, Rajan; George, Lindsey; Strong, Alanna.
502 $b Ph.D. $c University of Pennsylvania $d 2025.
520 $a Phenylketonuria (PKU), the most common inborn error of metabolism, is an autosomal recessive disorder caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. PAH converts phenylalanine (Phe) to tyrosine (Tyr), and impaired activity of PAH leads to the accumulation of blood Phe to neurotoxic levels. Despite existing dietary and medical treatments, chronic Phe elevations persist in most patients, causing neurological and cognitive deficits, particularly those with the most frequent pathogenic variants, such as c.1222C>T (p.R408W) and c.842C>T (p.P281L). Genome editing has the unique ability to directly correct these pathogenic variants and offers the potential for durable and curative therapies to address the unmet medical needs of PKU patients. Through this work, we have established a pipeline to rapidly screen and optimize prime editing or base editing strategies in vitro and deploy them in vivo with either lipid nanoparticles (LNPs) or adeno-associated viral (AAV) vectors on a timescale of months. We created prime-edited variant-bearing hepatocyte cell lines with the aforementioned PAH variants, and in parallel, humanized PKU mouse models. In homozygous or compound heterozygous PKU mice, we observe complete and long-term durable normalization of blood Phe levels (>90% reduction) as soon as 48 hours after treatment, with whole-liver corrective PAH editing as high as >50% with either prime editing or base editing. We have developed therapeutic leads for R408W and P281L to permanently normalize blood Phe levels and definitively treat PKU in these patients-on track for early-phase clinical trials within a few years. Together, these findings support the development of gene-editing therapies as definitive treatments for PKU and establish a framework for the nomination and validation of base and prime editing therapies for PKU and other hepatic inborn errors of metabolism.
546 $a English
590 $a School code: 0175
650 4 $a Genetics. $3 530508
650 4 $a Therapy. $3 3343697
650 4 $a Nanoscience. $3 587832
653 $a Gene editing
653 $a Gene therapy
653 $a Genetic medicine
653 $a Metabolism
653 $a Phenylketonuria
690 $a 0369
690 $a 0565
690 $a 0212
710 2 $a University of Pennsylvania. $b Cell and Molecular Biology. $e degree granting institution. $3 3824999
720 1 $a Musunuru, Kiran $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-12A.
790 $a 0175
791 $a Ph.D.
792 $a 2025
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31994101